Fig. 3: Pharmacological effects (upper panel showing ketamine effects and lower panel showing placebo effects) on different vigilance stages and relative median vigilance in MDD patients. | Translational Psychiatry

Fig. 3: Pharmacological effects (upper panel showing ketamine effects and lower panel showing placebo effects) on different vigilance stages and relative median vigilance in MDD patients.

From: EEG-vigilance regulation is associated with and predicts ketamine response in major depressive disorder

Fig. 3

A1, B1 Responders showed a larger decrease at stage A1 and a larger increase at stage B2/3 compared to non-responders. No significant difference was found between ketamine and placebo. The mean percentage and the corresponding error bar (representing ±1 standard error) were depicted in the figure. A2, B2 Mean median vigilance (averaged across start-pre and end-pre) and the corresponding error bar (represent ±1 standard error) were depicted in the figure. The median vigilance of responders decreased faster compared to non-responders. No significant difference was found between ketamine and placebo. Responders (and non-responders) were defined based on the response following ketamine infusion throughout the analysis.

Back to article page